Омализумаб (Ксолар): принципы действия, эффективность и безопасность

1. Чучалин А.Г. (ред.). Рациональная фармакотерапия заболеваний органов дыхания. М.: Литера; 2004

2. Holgate S. The epidemic of asthma and allergy. J. Roy. Soc. Med. 2004; 97 (3): 103–110.

3. Holgate S.T. Lessons learnt from the epidemic of asthma. Quart. J. Med. 2004; 97 (5): 247–257.

4. Global initiative fot asthma (GINA); http://www.ginasthma.com. November 2006

5. Barnes P. New drugs for asthma. Nat. Rev. Drug Discov. 2004; 3 (10): 831–847.

6. Canonica G.W. Treating asthma as an inflammatory disease. Chest 2006; 130 (suppl. 1): 21S–28S.

7. Ames S.A., Gleeson C.D., Kirpatrick P. Omalizumab. Nat. Rev. Drug Discov. 2004; 3 (3): 199–200.

8. Yanagihara Y. Regulatory mechanisms of human IgE synthesis. Allergol. Intern. 2003; 52 (3): 1–12.

9. Hamelmann E., Rolink!Werninghaus C., Wahn U. From IgE to anti-IgE: where we stand? Allergy 2002; 57: 983–994.

10. Takahashi K., Ra C. The high affinity IgE receptor (FcεRI) as a target for anti-allergic agents. Allergol. Intern. 2005; 54 (1): 1–5.

11. Owen C.T. Immunoglobulin E: role in astma and allergic diseases: lessons from the clinic. Pharmacol. Ther. 2007; 113 (1): 121–133.

12. Avila P.C. Does anti–IgE therapy help in asthma? Efficacy and controversies. Annu. Rev. Med. 2007; 58: 185–203.

13. Ruffin C.G., Busch B. Omalizumab: a recombinant humanized anti-IgE anti-body for allergic asthma. Am. J. HlthSyst. Pharm. 2004; 61 (14): 1449–1459.

14. Kambayashi T., Koretzky G.A. Proximal signaling events in FcεRI-mediated mast cell activation. J. Allergy Clin. Immunol. 2007; 119 (3): 544–552.

15. Busse W.W. Anti-immunoglobulin E (Omalizumab) therapy in allergic asthma. Am. J. Respir. Crit. Care Med. 2001; 164: S12–S17.

16. Marcus P. Incorporating anti-IgE (Omalizumab) therapy into pulmonary medicine practice. Chest 2006; 129 (2): 466–474.

17. Fachy J.V., Fleming H.E., Wong H.H. et al. The effect of an anti-IgE mono-clonal antibody on the earlyand late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1997; 155: 1828–1834.

18. Soler M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduced exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001; 18: 254–261.

19. Busse W.W., Corren J., Lanier B.Q. et al. Omalizumab, antiIgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001; 108: 184–190.

20. Baena!Cagnani C.E., Passalacqua G., Gomez M. et al. New perspectives in the treatment of allergic rhinitis and asthma in children. Curr. Opin. Allergy Clin. Immunol. 2007; 7: 201–206.

21. Milgrom H., Berger W., Nayak A. et al. Treatment of childhood asthma with anti-immunoglobulin ε antibody (omalizumab). Pediatrics 2001; 108; E 36.

22. Holgate S.T., Chuchalin A., Hebert J. и др. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy. 2004; 34: 632–638

23. Ayres J.G., Higgins B., Chilvers E.R. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004; 59: 701–708.

24. Holgate S.T., Djukanovic R., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update of anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 2005; 35: 408–416.

25. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur. J. Pharmacol. 2006; 533 (1–3): 302–307.

26. Chapman K.R., Cartier A., Hebert J. et al. The role of omalizumab in the treatment of severe allergic asthma. Can. Respir. J. 2006; 13 (suppl. B): 1B–9B.

27. Humbert M., Holgate S., Boulet L.-P., Bousquet J. Asthma control or severity: that is the question. Allergy 2007; 62: 95–101.

28. Strunk R.C., Bloomberg G.R. Omalizumab for asthma. N. Engl. J. Med. 2006; 354: 2689–2695.

29. Pichler W.J. Adverse side-effects to biological agents. Allergy 2006; 61: 912–920.

30. Vignola A.M., Humbert M., Bousquet J. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59: 709–717.

31. Casale T.B., Condemi J., Laforce C. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. J. A. M. A. 2001; 286: 2956–2967.

32. Kuehr J., Brauburger J., Zielen S. Efficacy of a combination treatment with anti-IgE plus specific immunotherapy in polysensitised children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2002; 109: 274–280.

33. Plewako H., Arvidsson M., Petruson K. et al. The effect of omalizumab on nasal allergic inflammation. J. Allergy Clin. Immunol. 2002; 110: 68–71.

34. Leung D.Y.M., Sampson H.A., Yunginger J.W. et al. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 2003; 348: 986–993.

35. Chehade M. IgE and non-IgE-mediated food allergy: treatment in 2007. Curr. Opin. Allergy Clin. Immunol. 2007; 7: 264–268.

36. Kraft S., Kinet J.!P. New developments in FcεRI regulation, function and inhibition. Nat. Rev. Immunol. 2007; 7 (5): 365–378.